PRIMARY STUDY
Differential Effects of D9 Tetrahydrocannabinol (THC)- and Cannabidiol (CBD)-Based Cannabinoid Treatments on Macrophage Immune Function In Vitro and on Gastrointestinal Inflammation in a Murine Model
Key Findings: This mouse model of gastric inflammation found that monocyte/macrophage exposure to cannabis inhibited macrophage nitrous oxide and inflammatory cytokine secretion, more profoundly with cannabis extract versus pure cannabinoids. This may lead to future therapeutic uses of cannabis in reducing inflammation associated with conditions like inflammatory bowel disease (IBD).
Type of Study: Laboratory Study
Study Result: Positive
Study Location(s): Israel
Year of Pub: 2022
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabinoid (unspecified), Synthetic Cannabinoid (unspecified), Endocannabinoid (unspecified)
Phytocannabinoid Source: Isolate
Ligands Studied: Pro-inflammatory cytokines
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration: In vitro
Cannabinoid Ratio: (THC : CBD) 0 : 0 
Dosing Regimen: CBD, THC, or cannabis extracts (5 µg/mL)
Clinical Relevance: All the tested treatments had an anti-inflammatory effect, but their specific effects differed based on the phenotype of the cells and cytokine production. The THC/CBD content may not be the best indicator for anti-inflammatory properties.
Additional Notes: Pharmacokinetic Study Data, Pharmacodynamic Study Data
Link to study
